Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 5, 2012, Pages 735-743

  Pierce, Brandon L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIOLOGICAL MARKER; GLITAZONE DERIVATIVE; HORMONE; INSULIN GLARGINE; METFORMIN; PIOGLITAZONE; PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CANCER SCREENING; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE DURATION; ETHNICITY; GLEASON SCORE; HELP SEEKING BEHAVIOR; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK REDUCTION;

ANDROGENS; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 84866752008     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.07.008     Document Type: Review

References (87)

1. Cowie C.C., Rust K.F., Byrd-Holt D.D., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National health and nutrition examination survey 1999-2002. Diabetes Care 2006, 29:1263-1268.
2. Cowie C.C., Rust K.F., Ford E.S., et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988 1994 and 2005-2006. Diabetes Care 2009, 32:287-294.
3. Gregg E.W., Cadwell B.L., Cheng Y.J., et al. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care 2004, 27:2806-2812.
4. Koopman R.J., Mainous A.G., Diaz V.A., et al. Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988-2000. Ann Fam Med 2005, 3:60-63.
5. Grote V.A., Becker S., Kaaks R. Diabetes mellitus type 2 - An independent risk factor for cancer?. Exp Clin Endocrinol Diabetes 2010, 118:4-8.
6. Vigneri P., Frasca F., Sciacca L., et al. Diabetes and cancer. Endocr Relat Cancer 2009, 16:1103-1123.
7. Kasper J.S., Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:2056-2062.
8. Bonovas S., Filioussi K., Tsantes A. Diabetes mellitus and risk of prostate cancer: A meta-analysis. Diabetologia 2004, 47:1071-1078.
9. Calton B.A., Chang S.C., Wright M.E., et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP diet and health study. Cancer Causes Control 2007, 18:493-503.
10. Kasper J.S., Liu Y., Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009, 124:1398-1403.
11. Leitzmann M.F., Ahn J., Albanes D., et al. Diabetes mellitus and prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Causes Control 2008, 19:1267-1276.
12. Waters K.M., Henderson B.E., Stram D.O., et al. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 2009, 169:937-945.
13. Velicer C.M., Dublin S., White E. Diabetes and the risk of prostate cancer: The role of diabetes treatment and complications. Prostate Cancer Prostatic Dis 2007, 10:46-51.
14. Gong Z., Neuhouser M.L., Goodman P.J., et al. Obesity, diabetes, and risk of prostate cancer: Results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006, 15:1977-1983.
15. Turner E.L., Lane J.A., Donovan J.L., et al. Association of diabetes mellitus with prostate cancer: Nested case-control study (prostate testing for cancer and treatment study). Int J Cancer 2011, 128:440-446.
16. Baradaran N., Ahmadi H., Salem S., et al. The protective effect of diabetes mellitus against prostate cancer: Role of sex hormones. Prostate 2009, 69:1744-1750.
17. Pourmand G., Salem S., Mehrsai A., et al. The risk factors of prostate cancer: A multicentric case-control study in Iran. Asian Pac J Cancer Prev 2007, 8:422-428.
18. Chodick G., Heymann A.D., Rosenmann L., et al. Diabetes and risk of incident cancer: A large population-based cohort study in Israel. Cancer Causes Control Jun 2010, 21:879-887.
19. Pierce B.L., Plymate S., Ostrander E.A., et al. Diabetes mellitus and prostate cancer risk. Prostate 2008, 68:1126-1132.
20. Wallström P., Bjartell A., Gullberg B., et al. A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. Br J Cancer 2009, 100:1799-1805.
21. Pelucchi C., Serraino D., Negri E., et al. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 2011, 21:835-841.
22. Li Q., Kuriyama S., Kakizaki M., et al. History of diabetes mellitus and the risk of prostate cancer: The Ohsaki cohort study. Cancer Causes Control 2010, 21:1025-1032.
23. Tseng C.H. Diabetes and risk of prostate cancer: A study using the national health insurance. Diabetes Care 2011, 34:616-621.
24. Rousseau M.C., Parent M.E., Pollak M.N., et al. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer 2006, 118:2105-2109.
25. Weiderpass E., Ye W., Vainio H., et al. Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 2002, 102:258-261.
26. Tavani A., Gallus S., Bertuzzi M., et al. Diabetes mellitus and the risk of prostate cancer in Italy. Eur Urol 2005, 47:313-317. Discussion:7.
27. Tavani A., Gallus S., Bosetti C., et al. Diabetes and the risk of prostate cancer. Eur J Cancer Prev 2002, 11:125-128.
28. Giovannucci E., Rimm E.B., Stampfer M.J., et al. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998, 9:3-9.
29. Zhu K., Lee I.M., Sesso H.D., et al. History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol 2004, 159:978-982.
30. Rodriguez C., Patel A.V., Mondul A.M., et al. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005, 161:147-152.
31. Lind M., Fahlén M., Eliasson B., et al. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diabetes 2012, 6:53-59.
32. Darbinian J.A., Ferrara A.M., Van Den Eeden S.K., et al. Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:628-635.
33. Pierce B.L., Ahsan H. Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk. Hum Hered 2010, 69:193-201.
34. Waters K.M., Wilkens L.R., Monroe K.R., et al. No association of type 2 diabetes risk variants and prostate cancer risk: The multiethnic cohort and PAGE. Cancer Epidemiol Biomarkers Prev 2011, 20:1979-1981.
35. Stevens V.L., Ahn J., Sun J., et al. HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. Prostate 2009, 70:601-607.
36. Fukui M., Tanaka M., Kadono M., et al. Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care 2008, 31:930-931.
37. Muller H., Raum E., Rothenbacher D., et al. Association of diabetes and Body Mass Index with levels of prostate-specific antigen: Implications for correction of prostate-specific antigen cutoff values?. Cancer Epidemiol Biomarkers Prev 2009, 18:1350-1356.
38. Werny D.M., Saraiya M., Gregg E.W. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol 2006, 164:978-983.
39. Sarma A.V., Burke J.P., Jacobson D.J., et al. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men. Diabetes Care 2008, 31:476-482.
40. Wu C., Moreira D.M., Gerber L., et al. Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis 2011, 14:326-331.
41. Skolarus T.A., Wolin K.Y., Grubb R.L. The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nat Clin Pract Urol 2007, 4:605-614.
42. Freedland S.J., Platz E.A. Obesity and prostate cancer: Making sense out of apparently conflicting data. Epidemiol Rev 2007, 29:88-97.
43. Discacciati A., Orsini N., Wolk A. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann Oncol 2012, 23:1665-1671.
44. Stewart S.B., Freedland S.J. Influence of obesity on the incidence and treatment of genitourinary malignancies. Urol Oncol 2011, 29:476-486.
45. Sarma A.V., Parsons J.K., McVary K., et al. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms-what do we know?. J Urol 2009, 182(6 Suppl):S32-S37.
46. Kim W.T., Yun S.J., Choi Y.D., et al. Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels. J Korean Med Sci 2011, 26:1214-1218.
47. Uzzo R.G., Wei J.T., Waldbaum R.S., et al. The influence of prostate size on cancer detection. Urology 1995, 46:831-836.
48. Carroll P., Coley C., McLeod D., et al. Prostate-specific antigen best practice policy-part I: Early detection and diagnosis of prostate cancer. Urology 2001, 57:217-224.
49. Schenk J.M., Kristal A.R., Arnold K.B., et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: Results from the prostate cancer prevention trial. Am J Epidemiol 2011, 173:1419-1428.
50. McNeal J.E. Normal histology of the prostate. Am J Surg Pathol 1988, 12:619-633.
51. Moses K.A., Utuama O.A., Goodman M., et al. The association of diabetes and positive prostate biopsy in a US veteran population. Prostate Cancer Prostatic Dis 2011, 15:70-74.
52. Moreira D.M., Anderson T., Gerber L., et al. The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes Control 2011, 22:977-983.
53. Hong S.K., Oh J.J., Byun S.S., et al. Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi ((≥12)-core prostate biopsy. Prostate 2012, 72:51-57.
54. Jayachandran J., Aronson W.J., Terris M.K., et al. Diabetes and outcomes after radical prostatectomy: Are results affected by obesity and race?. Results from the shared equal-access regional cancer hospital database. Cancer Epidemiol Biomarkers Prev 2010, 19:9-17.
55. Abdollah F., Briganti A., Suardi N., et al. Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy?. Prostate Cancer Prostatic Dis 2011, 14:74-78.
56. Kang J., Chen M.H., Zhang Y., et al. Type of Diabetes Mellitus and the odds of Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:e463-e467.
57. Mitin T., Chen M.H., Zhang Y., et al. Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy. J Urol 2011, 186:2233-2237.
58. Gallagher E.J., Leroith D. Diabetes, cancer, and metformin: Connections of metabolism and cell proliferation. Ann N Y Acad Sci 2011, 1243:54-68.
59. Decensi A., Puntoni M., Goodwin P., et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila) 2010, 3:1451-1461.
60. Azoulay L., Dell'Aniello S., Gagnon B., et al. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 2011, 20:337-344.
61. Weng J.R., Chen C.Y., Pinzone J.J., et al. Beyond peroxisome proliferator-activated receptor gamma signaling: The multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 2006, 13:401-413.
62. Govindarajan R., Ratnasinghe L., Simmons D.L., et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007, 25:1476-1481.
63. Koro C., Barrett S., Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007, 16:485-492.
64. Pini T.M., Griffin M.R., Roumie C.L., et al. Use of thiazolidinediones does not affect prostate-specific antigen levels in men with diabetes. Cancer Epidemiol Biomarkers Prev 2009, 18:1937-1938.
65. Ferrara A., Lewis J.D., Quesenberry C.P., et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011, 34:923-929.
66. Murtola T.J., Tammela T.L., Lahtela J., et al. Antidiabetic medication and prostate cancer risk: A population-based case-control study. Am J Epidemiol 2008, 168:925-931.
67. Giovannucci E., Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007, 132:2208-2225.
68. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004, 53(Suppl 3):S16-S21.
69. Stocks T., Lukanova A., Rinaldi S., et al. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 2007, 120:2678-2686.
70. Neuhouser M.L., Till C., Kristal A., et al. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: Results from the prostate cancer prevention trial. Cancer Prev Res (Phila) 2010, 3:279-289.
71. Lai G.Y., Helzlsouer K.J., Clipp S.L., et al. Association between C-peptide concentration and prostate cancer incidence in the CLUE II cohort study. Cancer Prev Res (Phila) 2010, 3:1334-1341.
72. Fowke J.H., Motley S.S., Cookson M.S., et al. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis 2007, 10:137-142.
73. Albanes D., Weinstein S.J., Wright M.E., et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 2009, 101:1272-1279.
74. Borugian M.J., Spinelli J.J., Sun Z., et al. Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:2164-2165.
75. Hubbard J.S., Rohrmann S., Landis P.K., et al. Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology 2004, 63:253-258.
76. Joshu C.E., Prizment A.E., Dluzniewski P.J., et al. Glycated hemoglobin and cancer incidence and mortality in the atherosclerosis in communities (ARIC) study, 1990-2006. Int J Cancer 2011.
77. Pitteloud N., Hardin M., Dwyer A.A., et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005, 90:2636-2641.
78. Roddam A.W., Allen N.E., Appleby P., et al. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008, 100:170-183.
79. Hsing A.W., Chu L.W., Stanczyk F.Z. Androgen and prostate cancer: Is the hypothesis dead?. Cancer Epidemiol Biomarkers Prev 2008, 17:2525-2530.
80. Calistro Alvarado L. Population differences in the testosterone levels of young men are associated with prostate cancer disparities in older men. Am J Hum Biol 2010, 22:449-455.
81. Kasper J.S., Liu Y., Pollak M.N., et al. Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control 2008, 19:703-710.
82. Laaksonen D.E., Niskanen L., Punnonen K., et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004, 27:1036-1041.
83. Monzavi R., Cohen P. IGFs and IGFBPs: Role in health and disease. Best Pract Res Clin Endocrinol Metab 2002, 16:433-447.
84. Roddam A.W., Allen N.E., Appleby P., et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: Analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008, 149:461-471. W83-8.
85. Zhang W., Hu R. Why does diabetes offer protective effects against prostate cancer?. The possible role of its microvascular complications. Med Hypotheses 2010, 74:242-243.
86. Beyazit Y., Kekilli M., Purnak T. Are microvascular complications of diabetes mellitus really associated with prostate cancer?. Med Hypotheses 2010, 75:134-135.
87. Snyder C.F., Stein K.B., Barone B.B., et al. Does pre-existing diabetes affect prostate cancer prognosis?. A systematic review. Prostate Cancer Prostatic Dis 2010, 13:58-64.